Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.

When Does Alzheimer′s Disease Really Start? The Role of Biomarkers

Open access
Lloret, Ana, Esteve, Daniel, Lloret, Maria-Angeles, Cervera-Ferri, Ana, Lopez, Begoña, Nepomuceno, Mariana, Monllor, Paloma · 2019 · International Journal of Molecular Sciences

Abstract

While Alzheimer’s disease (AD) classical diagnostic criteria rely on clinical data from a stablished symptomatic disease, newer criteria aim to identify the disease in its earlier stages. For that, they incorporated the use of AD’s specific biomarkers to reach a diagnosis, including the identification of Aβ and tau depositions, glucose hypometabolism, and cerebral atrophy. These biomarkers created a new concept of the disease, in which AD’s main pathological processes have already taken place decades before we can clinically diagnose the first symptoms. Therefore, AD is now considered a dynamic disease with a gradual progression, and dementia is its final stage. With that in mind, new models were proposed, considering the orderly increment of biomarkers and the disease as a continuum, or the variable time needed for the disease’s progression. In 2011, the National Institute on Aging and the Alzheimer’s Association (NIA-AA) created separate diagnostic recommendations for each stage of the disease continuum—preclinical, mild cognitive impairment, and dementia. However, new scientific advances have led them to create a unifying research framework in 2018 that, although not intended for clinical use as of yet, is a step toward shifting the focus from the clinical symptoms to the biological alterations and toward changing the future diagnostic and treatment possibilities. This review aims to discuss the role of biomarkers in the onset of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms20225536

Cites

118 of 118 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Evolution of the different AD biomarkers along time. Cerebrospinal fluid (CSF) Aβ and Pittsburgh compound B positron emission tomography (PiB-PET) abnormalities appear first followed by an increase in CSF tau levels and finally by structural alterations evidenced by magnetic resonance imaging (MRI) and fluoro-d-glucose tracer positron emission tomography (FDG-PET) (blue). The presence of risk factor determines the onset of the disease. People with low risk factors will present cognitive decline later than those with high risk factor (green).
Figure 1 Evolution of the different AD biomarkers along time. Cerebrospinal fluid (CSF) Aβ and Pittsburgh compound B positron emission tomography (PiB-PET) abnormalities appear first followed by an increase in CSF tau levels and finally by structural alterations evidenced by magnetic resonance imaging (MRI) and fluoro-d-glucose tracer positron emission tomography (FDG-PET) (blue). The presence of risk factor determines the onset of the disease. People with low risk factors will present cognitive decline later than those with high risk factor (green).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 117 references

Cited by

See all 146

Metadata

Authors
Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P.
Affiliations
  • Universitat de València (ES)
  • Department of Clinic Neurophysiology. University Clinic Hospital of Valencia, Avda. Blasco Ibanez, 19, 46010 Valencia, Spain
  • Department of Human Anatomy and Embriology, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain
  • Hospital Clínico Universitario de Valencia (ES)
Corresponding author
Lloret, Ana
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2019-11-06
Volume
20
Issue
22
Pages
5536
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2985526400
Cited by
131
References
117
Citations by year
2026: 21 · 2025: 22 · 2024: 24 · 2023: 21 · 2022: 22 · 2021: 19 · 2020: 2
FWCI
1.81
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, other-oa)
Funders
Ministerio de Economía, Industria y Competitividad, Gobierno de España (SAF2016-75508-R)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords
Alzheimer's disease, disease onset, biomarkers, preclinical Alzheimer's disease, mild cognitive impairment, dementia, amyloid-beta, tau protein, glucose hypometabolism, brain atrophy, NIA-AA criteria, disease continuum, early diagnosis
MeSH terms
Alzheimer Disease, Humans, Risk Factors, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: When Does Alzheimer′s Disease Really Start? The Role of Biomarkers. https://app.cochat.ai/papers/10.3390/ijms20225536
The paper
Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2019). When Does Alzheimer′s Disease Really Start? The Role of Biomarkers. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms20225536

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.